EXEL

$70.091.01%0.70

Dopo l'orario di chiusura: 70.13+0.04 +0.06%

Exelixis Inc (EXEL)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$69.39

Aprire:

$69.53

Volume 24 ore:

4,636,551

Volume relativo:

1.81

Capitalizzazione di mercato:

$17.10B

Reddito:

$2.38B

Utile/perdita netta:

$833.42M

Rapporto P/E:

23.23

EPS:

$3.02

Flusso di cassa netto:

$917.69M

1W Prestazione:

+7.65%

1M Prestazione:

+20.04%

6M Prestazione:

+60.46%

1Y Prestazione:

+81.25%

Intervallo 1D:

$69.15$72.01

Intervallo di 1 settimana:

$64.75$72.10

Portata 52W:

$36.00$72.10

Profilo aziendale di Exelixis Inc (EXEL)

Nome

Exelixis Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

(650) 837-7000

Indirizzo

1851 HARBOR BAY PARKWAY, ALAMEDA, CA, USA

Dipendente

1,077

@exelixisinc

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di EXEL su X

Confronta EXEL con VRTX, REGN, MRNA, ARGX, ONC

Azioni	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EXEL Exelixis Inc	$17.10B	$2.32B	$782.57M	$1.17B	$3.02
VRTX Vertex Pharmaceuticals Inc	$140.94B	$12.59B	$4.41B	$3.80B	$16.87
REGN Regeneron Pharmaceuticals Inc	$99.46B	$16.90B	$4.82B	$3.83B	$41.04
MRNA Moderna Inc	$88.17B	$2.23B	-$3.15B	-$1.24B	-$8.15
ARGX Argen X Se Adr	$55.03B	$4.16B	$1.29B	$734.26M	$19.58
ONC Beone Medicines Ltd Adr	$40.86B	$6.13B	$655.71M	$1.33B	$4.48

Exelixis Inc Azioni (EXEL) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-08-19	Iniziato	BMO Capital Markets	Market Perform
2026-08-06	Downgrade	Leerink Partners	Outperform → Market Perform
2026-06-25	Resumed	Truist	Hold
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Downgrade	BofA Securities	Neutral → Underperform
2025-11-18	Iniziato	Wolfe Research	Peer Perform
2025-11-03	Downgrade	Guggenheim	Buy → Neutral
2025-10-21	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-09-19	Resumed	Barclays	Equal Weight
2025-09-17	Resumed	Barclays	Equal Weight
2025-09-17	Iniziato	Goldman	Buy
2025-07-08	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Aggiornamento	Stephens	Equal-Weight → Overweight
2025-02-24	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Downgrade	Oppenheimer	Outperform → Perform
2024-12-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Downgrade	BofA Securities	Buy → Neutral
2024-10-16	Reiterato	RBC Capital Mkts	Outperform
2024-09-19	Iniziato	UBS	Neutral
2024-04-11	Downgrade	Barclays	Overweight → Equal Weight
2023-12-19	Iniziato	BTIG Research	Buy
2023-12-15	Iniziato	Citigroup	Buy
2023-09-26	Iniziato	H.C. Wainwright	Buy
2023-08-22	Reiterato	Oppenheimer	Outperform
2023-08-08	Iniziato	SVB Securities	Market Perform
2023-07-11	Resumed	Morgan Stanley	Equal-Weight
2023-05-10	Resumed	Piper Sandler	Overweight
2023-03-09	Iniziato	Wells Fargo	Overweight
2023-01-26	Iniziato	Credit Suisse	Outperform
2022-10-18	Iniziato	JMP Securities	Mkt Outperform
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-11-03	Resumed	Jefferies	Buy
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Reiterato	H.C. Wainwright	Buy
2021-06-15	Iniziato	H.C. Wainwright	Buy
2021-05-18	Resumed	Goldman	Sell
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-03-12	Iniziato	Wolfe Research	Outperform
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Iniziato	SunTrust	Buy
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-03-18	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Iniziato	Goldman	Neutral
2018-09-10	Iniziato	Morgan Stanley	Underweight
2018-05-11	Reiterato	Needham	Buy
2017-10-17	Reiterato	Needham	Buy
2017-10-17	Reiterato	RBC Capital Mkts	Outperform
2017-10-16	Reiterato	SunTrust	Buy
2017-09-22	Downgrade	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-09-12	Reiterato	Needham	Buy
2017-07-14	Iniziato	SunTrust	Buy
2017-03-31	Iniziato	Needham	Buy
2017-03-16	Iniziato	Oppenheimer	Perform
2017-02-28	Downgrade	Stifel	Buy → Hold
2016-11-03	Iniziato	Deutsche Bank	Buy
2016-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-09-15	Reiterato	Stifel	Buy

Exelixis Inc Azioni (EXEL) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2026-01-02	2025-01-03	2023-12-29	2022-12-30	2021-12-31
Revenue USD (M)	2,320.13	2,168.70	1,830.21	1,611.06	987.54
Cost of revenue USD (M)	83.70	76.22	72.55	57.91	36.27
Gross profit USD (M)	-	-	1,757.66	1,553.15	951.27
Research and development USD (M)	825.00	910.41	1,044.07	891.81	547.85
Operating expenses USD (M)	1,447.94	1,564.08	1,586.78	1,351.67	841.21
Operating income USD (M)	872.19	604.62	170.89	201.48	110.06
Income before tax USD (M)	-	-	170.89	201.48	130.84
Income tax expense USD (M)	158.64	160.37	49.76	52.07	19.06
Net income USD (M)	782.57	521.27	207.77	182.28	111.78
Basic EPS USD/shares	2.88	1.80	0.65	0.57	0.36
Diluted EPS USD/shares	2.78	1.76	0.65	0.56	0.35
Basic weighted shares shares (M)	271.57	290.03	318.15	321.53	308.27
Diluted weighted shares shares (M)	281.86	296.13	321.46	324.56	318.00
Selling, general and administrative USD (M)	518.73	492.13	542.71	459.86	293.36

Exelixis Inc Azioni (EXEL) insider trading

Beckerle Mary CAug 10 '26
Director
Transazione
Sale
Costo
$53.66
#Azioni
9,812
Valore ($)
526,512
#Azioni Totale
16,079
MARY BECKERLEAug 10 '26
Director
Transazione
Proposed Sale
Costo
$53.66
#Azioni
9,812
Valore ($)
526,496
#Azioni Totale
0
JACK L WYSZOMIERSKIJun 01 '26
Director
Transazione
Proposed Sale
Costo
$50.55
#Azioni
3,925
Valore ($)
198,409
#Azioni Totale
0
Eckhardt Sue GailJun 01 '26
Director
Transazione
Proposed Sale
Costo
$50.87
#Azioni
9,812
Valore ($)
499,136
#Azioni Totale
0
Eckhardt Sue GailJun 01 '26
Director
Transazione
Sale
Costo
$50.14
#Azioni
9,812
Valore ($)
491,974
#Azioni Totale
16,079
WYSZOMIERSKI JACK LJun 01 '26
Director
Transazione
Sale
Costo
$50.55
#Azioni
3,925
Valore ($)
198,409
#Azioni Totale
284,384
Aftab DanaMay 26 '26
EVP, Research and Development
Transazione
Sale
Costo
$50.35
#Azioni
43,451
Valore ($)
2,187,758
#Azioni Totale
594,741
DANA T AFTABMay 26 '26
Officer
Transazione
Proposed Sale
Costo
$50.35
#Azioni
43,451
Valore ($)
2,187,758
#Azioni Totale
0
PATRICK JOSEPH HALEYMay 20 '26
Officer
Transazione
Proposed Sale
Costo
$49.81
#Azioni
32,110
Valore ($)
1,599,444
#Azioni Totale
0
Haley Patrick J.May 20 '26
EVP, Commercial
Transazione
Sale
Costo
$49.81
#Azioni
32,110
Valore ($)
1,599,399
#Azioni Totale
357,638

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Beckerle Mary C	Director	Aug 10 '26	Sale	$53.66	9,812	526,512	16,079
MARY BECKERLE	Director	Aug 10 '26	Proposed Sale	$53.66	9,812	526,496	0
JACK L WYSZOMIERSKI	Director	Jun 01 '26	Proposed Sale	$50.55	3,925	198,409	0
Eckhardt Sue Gail	Director	Jun 01 '26	Proposed Sale	$50.87	9,812	499,136	0
Eckhardt Sue Gail	Director	Jun 01 '26	Sale	$50.14	9,812	491,974	16,079
WYSZOMIERSKI JACK L	Director	Jun 01 '26	Sale	$50.55	3,925	198,409	284,384
Aftab Dana	EVP, Research and Development	May 26 '26	Sale	$50.35	43,451	2,187,758	594,741
DANA T AFTAB	Officer	May 26 '26	Proposed Sale	$50.35	43,451	2,187,758	0
PATRICK JOSEPH HALEY	Officer	May 20 '26	Proposed Sale	$49.81	32,110	1,599,444	0
Haley Patrick J.	EVP, Commercial	May 20 '26	Sale	$49.81	32,110	1,599,399	357,638

Exelixis Inc Borsa (EXEL) Ultime notizie

Oct 30, 2026

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

Exelixis stock hits all-time high at 65.62 USD By Investing.com - Investing.com India

Oct 28, 2026

Oct 27, 2026

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock - MarketBeat

Oct 26, 2026

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.

Oct 26, 2026

Oct 24, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research

Oct 22, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 22, 2026